| FT. MYERS, Fla., July 18, 2012 /PRNewswire/ -- NeoGenomics, Inc. (NASD OTC BB: NGNM) , a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched 20 new molecular assays thus far in 2012 and that it expects to validate another 15-20 molecular assays by the end of 2012. NeoGenomics also announced that it is in the process of launching a series of new NeoTYPE™ Cancer Profile Panels in conjunction with this significantly expanded...continued NGNM investor stock neogenomics |
Wednesday, July 18, 2012
NeoGenomics Significantly Expands Molecular Testing Menu and Launches NeoTYPE(tm) Cancer Profile Panels
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment